Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

NCT01536067 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped funding was withdrawn

Conditions

Waldenström Macroglobulinemia

Interventions

BIOLOGICAL: ofatumumab
DRUG: bortezomib
OTHER: laboratory biomarker analysis

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]
[object Object]